Alopecia areata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition.
Alopecia areata and asthma are strongly linked, particularly through the inflammatory protein IL-33, suggesting a shared biological pathway and potential for targeted treatments like dupilumab.